Altman Peter 4

What Happened Peter Altman, President, CEO and a director of BioCardia, reported open-market purchases of common stock. He acquired 5,500 shares on 2026-07-08 at a weighted-average price of $0.97 ($5,335), 1,000 shares on 2026-07-09 at $0.90 ($900), and 1,000 shares on 2026-07-10 at $0.94 ($940) — a total of 7,500 shares for roughly $7,175. These transactions are purchases (transaction code P), which are generally viewed as insider buying rather than selling.

Key Details

• Transaction dates and prices: 7/8/2026 — 5,500 sh @ $0.97 (weighted avg; executed at $0.92–$1.05 per F1); 7/9/2026 — 1,000 sh @ $0.90; 7/10/2026 — 1,000 sh @ $0.94.
• Total reported value: ~ $7,175.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: F1 notes the 7/8 purchase was executed in multiple trades priced between $0.92 and $1.05; the filer will provide a breakdown on request to the SEC.
• Timeliness: Form 4 filed 2026-07-10 for transactions occurring 7/8–7/10 — reported within the SEC’s two-business-day window (i.e., not late).

Context These are small-dollar open-market purchases by the company’s chief executive, not option exercises or gifts. The filing is factual and does not state motivation; purchases can be interpreted by investors as a sign of insider buying interest but do not guarantee future performance.